



Malmö 31 March 2023

PRESS RELEASE

BioStock article: Aptahem's CEO sees continued interest in Apta-1

Aptahem is progressing with its first clinical study with sepsis candidate Apta-1. The company has also ramped up activities to showcase the candidate at domestic and international industry conferences, such as BIO-Europe Spring in Switzerland and TIDES Asia in Japan. BioStock talked to CEO Mikael Lindstam to learn more.

Read the full interview with Aptahem's CEO Mikael Lindstam at [biostock.se](https://www.biostock.se):

<https://www.biostock.se/en/2023/03/aptahems-ceo-sees-continued-interest-in-apta-1/>

For further information:

Aptahem AB

Mikael Lindstam, CEO

Tel: +46 (0)766-33 36 99

E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.